Copyright
©2009 Baishideng. All rights reserved.
World J Gastrointest Oncol. Oct 15, 2009; 1(1): 38-40
Published online Oct 15, 2009. doi: 10.4251/wjgo.v1.i1.38
Published online Oct 15, 2009. doi: 10.4251/wjgo.v1.i1.38
Pancreatic cancer: A model cancer for the study of the therapeutic effects of anticoagulants
Anthony Maraveyas, The Queen’s Centre for Oncology and Haematology, Hull and York Medical School, Castle Hill Hospital, Castle Road, Hull, HU16 5JQ, United Kingdom
Author contributions: Maraveyas A wrote this editorial.
Correspondence to: Anthony Maraveyas, FRCP, PhD, Senior Lecturer and Consultant in Medical Oncology, Department of Haematology Oncology, Hull and York Medical School, Castle Hill Hospital, Castle Road, Hull, HU16 5JQ, United Kingdom. a.maraveyas@hull.ac.uk
Telephone: +44-1482-461318 Fax: +44-1482-607739
Received: February 23, 2009
Revised: July 26, 2009
Accepted: August 2, 2009
Published online: October 15, 2009
Revised: July 26, 2009
Accepted: August 2, 2009
Published online: October 15, 2009
Abstract
Cancer-related thromboembolic disease is a well recognized syndrome since first described by Armand Trousseau in 1865. Preventing the morbidity and mortality related to thromboembolism in these patients is becoming a priority research area with the advent of new anti-coagulants. It is only recently that randomized trials of improved quality are been undertaken to study this question. Many of these trials however are still not accounting for the heterogeneity of “cancer” in terms of anatomical site, histology, stage and treatment. This editorial review highlights why pancreatic cancer may serve as a model malignancy to study this question.
Keywords: Pancreatic Cancer, Vascular, Thromboembolism, Vascular thromboembolic disease, Heparin, Anticoagulants